Contributors |
|
v | |
Acknowledgments |
|
xix | |
Preface |
|
xxi | |
Chapter 1 Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy |
|
1 | (74) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 | (6) |
|
1.1 Histaminergic system in the brain |
|
|
4 | (1) |
|
1.2 Histaminergic receptors in the brain |
|
|
5 | (1) |
|
1.3 Histamine in brain diseases |
|
|
5 | (3) |
|
2 Histaminergic system alterations in Parkinson's disease |
|
|
8 | (2) |
|
2.1 Histamine concentration in PD |
|
|
8 | (1) |
|
2.2 Histaminergic nerve fibers in PD |
|
|
8 | (1) |
|
2.3 Histaminergic gene and receptors in PD |
|
|
9 | (1) |
|
3 Our own investigations on histamine modulation of Parkinson's disease |
|
|
10 | (7) |
|
3.1 Methodological consideration |
|
|
10 | (1) |
|
|
10 | (1) |
|
3.3 Modulation of histaminergic agents |
|
|
10 | (1) |
|
|
11 | (3) |
|
|
14 | (1) |
|
3.6 Biochemical measurements |
|
|
15 | (1) |
|
3.7 Neuropathology of Parkinson's disease |
|
|
15 | (2) |
|
|
17 | (19) |
|
4.1 MPTP induced PD mouse model |
|
|
17 | (11) |
|
4.2 Blood-brain barrier disturbances in PD |
|
|
28 | (1) |
|
4.3 Cerebral blood flow in PD |
|
|
28 | (1) |
|
4.4 Brain edema and volume swelling in PD |
|
|
28 | (2) |
|
4.5 Brain pathology in PD |
|
|
30 | (6) |
|
5 Histamine modulating agent's for neuroprotection in PD |
|
|
36 | (8) |
|
5.1 Histamine H3 receptor inverse agonist BF2649 |
|
|
36 | (2) |
|
5.2 Histamine H3 receptor antagonist and partial H4 receptor agonist clobenpropit |
|
|
38 | (2) |
|
5.3 Nanowired delivery of histaminergic agents |
|
|
40 | (4) |
|
|
44 | (4) |
|
6.1 Conclusion and future perspective |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
|
48 | (27) |
Chapter 2 Ultra early molecular biologic diagnosis of malignant and neurodegenerative diseases by the immunospecific profiles of the proteins markers of the surface of the mobilized autologous hematopoietic stem cells |
|
75 | (22) |
|
|
|
|
|
76 | (3) |
|
|
79 | (3) |
|
|
82 | (5) |
|
|
87 | (6) |
|
|
93 | (1) |
|
|
94 | (1) |
|
|
94 | (3) |
Chapter 3 Neuroprotective effects of insulin like growth factor-1 on engineered metal nanoparticles Ag, Cu and Al induced blood-brain barrier breakdown, edema formation, oxidative stress, upregulation of neuronal nitric oxide synthase and brain pathology |
|
97 | (26) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98 | (2) |
|
|
100 | (2) |
|
|
100 | (1) |
|
2.2 Administration of nanoparticles |
|
|
100 | (1) |
|
2.3 Insulin like growth factor-1 (IGF-1) administration |
|
|
100 | (1) |
|
2.4 Measurement of oxidative stress parameters in the brain |
|
|
100 | (1) |
|
2.5 Blood-brain barrier and neuronal injury |
|
|
101 | (1) |
|
2.6 Brain edema formation |
|
|
101 | (1) |
|
2.7 Morphological analysis |
|
|
101 | (1) |
|
2.8 Nitric oxide activity |
|
|
101 | (1) |
|
2.9 Statistical analyses of data |
|
|
102 | (1) |
|
|
102 | (7) |
|
3.1 Nanoparticles intoxication induces oxidative stress |
|
|
102 | (2) |
|
3.2 Nanoparticles intoxication induces BBB disruption |
|
|
104 | (1) |
|
3.3 Nanoparticles intoxication induces brain edema |
|
|
104 | (1) |
|
3.4 Nanoparticles intoxication induces neuronal nitric oxide synthase upregulation |
|
|
104 | (1) |
|
3.5 Nanoparticles intoxication induces neuronal injuries |
|
|
104 | (3) |
|
3.6 Effect of insulin like growth factor-1 (IGF-1) on nanoneurotoxicity |
|
|
107 | (2) |
|
|
109 | (1) |
|
|
110 | (1) |
|
|
111 | (1) |
|
|
111 | (12) |
Chapter 4 Methamphetamine exacerbates pathophysiology of traumatic brain injury at high altitude. Neuroprotective effects of nanodelivery of a potent antioxidant compound H-290/51 |
|
123 | (72) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
124 | (6) |
|
1.1 Brain function at high altitude |
|
|
126 | (4) |
|
2 Methamphetamine at high altitude |
|
|
130 | (3) |
|
2.1 History of methamphetamine |
|
|
130 | (3) |
|
3 Traumatic brain injury at high altitude |
|
|
133 | (2) |
|
3.1 Secondary brain injury processes are affected at high altitude |
|
|
134 | (1) |
|
4 Our observation on methamphetamine and traumatic brain injury at high altitude |
|
|
135 | (6) |
|
4.1 Methodological consideration |
|
|
135 | (1) |
|
4.2 Concussive head injury |
|
|
136 | (1) |
|
4.3 Pathophysiology of brain injury |
|
|
137 | (2) |
|
|
139 | (2) |
|
|
141 | (1) |
|
|
141 | (8) |
|
5.1 Physiological parameters at normobaric control group |
|
|
141 | (5) |
|
5.2 Blood-brain barrier permeability in normobaric group |
|
|
146 | (2) |
|
5.3 Cerebral blood flow in control at normobaric group |
|
|
148 | (1) |
|
5.4 Brain edema and volume swelling in control at normobaric group |
|
|
148 | (1) |
|
|
149 | (2) |
|
6.1 Beta catenin level at normobaric group |
|
|
149 | (2) |
|
|
151 | (2) |
|
7.1 Neuronal injury at normobaric group |
|
|
151 | (2) |
|
8 Glial fibrillary acidic protein immunoreactivity |
|
|
153 | (1) |
|
8.1 GFAP reactivity in control at normobaric group |
|
|
153 | (1) |
|
9 Myelin damage of control at normobaric group |
|
|
154 | (2) |
|
9.1 Myelin damage in CHI at normobaric group |
|
|
154 | (1) |
|
9.2 Myelin damage at high altitude group |
|
|
154 | (2) |
|
9.3 Myelin damage in CHI at high altitude group |
|
|
156 | (1) |
|
10 Endothelial distortion at normobaric group |
|
|
156 | (1) |
|
10.1 Endothelial distortion in CHI at normobaric group |
|
|
156 | (1) |
|
10.2 Endothelial distortion at high altitude group |
|
|
156 | (1) |
|
10.3 Endothelial distortion in CHI at high altitude group |
|
|
156 | (1) |
|
11 Treatment with antioxidant drug H-290/51 |
|
|
157 | (3) |
|
11.1 Treatment with nanowired H-290/51 |
|
|
158 | (2) |
|
|
160 | (3) |
|
|
163 | (1) |
|
|
164 | (1) |
|
|
164 | (1) |
|
|
164 | (31) |
Chapter 5 Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation |
|
195 | (16) |
|
|
|
|
|
|
|
|
196 | (1) |
|
|
197 | (2) |
|
2.1 Human glioblastoma cells |
|
|
197 | (1) |
|
|
197 | (1) |
|
2.3 Proteomics-based comparative mapping of GBM cells |
|
|
197 | (1) |
|
|
198 | (1) |
|
2.5 Pharmaceutical agents |
|
|
198 | (1) |
|
2.6 Method of in vitro testing |
|
|
198 | (1) |
|
|
198 | (1) |
|
|
199 | (4) |
|
3.1 Characteristics of T98G line of GBM cells after radiation treatment |
|
|
199 | (1) |
|
3.2 Proteomics-based comparative mapping of T98G line cell of GBM after radiation treatment |
|
|
199 | (1) |
|
3.3 Testing the effect of cytotoxic and targeted agents on an in vitro model of recurrent GBM |
|
|
200 | (3) |
|
|
203 | (3) |
|
|
206 | (1) |
|
Ethics approval and consent to participate |
|
|
206 | (1) |
|
|
207 | (1) |
|
|
207 | (1) |
|
|
207 | (4) |
Chapter 6 Cerebrolysin restores balance between excitatory and inhibitory amino acids in brain following concussive head injury. Superior neuroprotective effects of TiO2 nanowired drug delivery |
|
211 | (58) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
212 | (2) |
|
|
214 | (8) |
|
|
214 | (1) |
|
|
215 | (1) |
|
|
215 | (1) |
|
2.4 Cerebrolysin treatment |
|
|
215 | (2) |
|
2.5 TiO2 nanowired cerebrolysin delivery |
|
|
217 | (1) |
|
|
217 | (1) |
|
2.7 Blood-brain barrier permeability |
|
|
217 | (1) |
|
2.8 Brain edema formation |
|
|
218 | (1) |
|
|
219 | (1) |
|
2.10 Measurement of amino acid neurotransmitters |
|
|
220 | (1) |
|
2.11 Physiological variables |
|
|
220 | (1) |
|
2.12 Behavioral parameters |
|
|
221 | (1) |
|
|
222 | (22) |
|
3.1 Physiological variables |
|
|
222 | (1) |
|
|
222 | (3) |
|
3.3 Excitatory amino acids aspartate and glutamate |
|
|
225 | (1) |
|
3.4 Inhibitory amino acids glycine and GABA |
|
|
225 | (5) |
|
3.5 Blood-brain barrier permeability |
|
|
230 | (1) |
|
3.6 Brain edema formation |
|
|
230 | (9) |
|
|
239 | (1) |
|
3.8 Effect of cerebrolysin in concussive head injury |
|
|
240 | (1) |
|
3.9 Physiological variables |
|
|
241 | (1) |
|
|
241 | (1) |
|
3.11 Excitatory amino acids in brain |
|
|
242 | (1) |
|
3.12 Inhibitory amino acids |
|
|
242 | (1) |
|
|
242 | (1) |
|
|
242 | (1) |
|
|
243 | (1) |
|
3.16 Nanodelivery of cerebrolysin |
|
|
243 | (1) |
|
|
244 | (4) |
|
|
248 | (1) |
|
|
249 | (1) |
|
|
249 | (20) |
Chapter 7 Neuromodulation as a basic platform for neuroprotection and repair after spinal cord injury |
|
269 | (32) |
|
|
|
|
|
|
|
270 | (1) |
|
2 Pathophysiology of SC injury and regeneration |
|
|
271 | (2) |
|
3 Strategy for treating SCI patients: Reanimation, neuroprotection and blood-brain barrier |
|
|
273 | (1) |
|
|
274 | (4) |
|
5 Surgical treatment of spasticity |
|
|
278 | (5) |
|
5.1 Intrathecal baclofen therapy (ITB) |
|
|
278 | (3) |
|
5.2 Spinal cord stimulation (SCS) |
|
|
281 | (2) |
|
6 Biomedical technologies in SCI treatment |
|
|
283 | (3) |
|
7 Prospects of integrating biomedical and bionic technologies |
|
|
286 | (2) |
|
|
288 | (2) |
|
|
290 | (1) |
|
|
290 | (1) |
|
Patient consent for publication |
|
|
290 | (1) |
|
|
290 | (1) |
|
|
290 | (11) |
Chapter 8 Superior antioxidant and anti-ischemic neuroprotective effects of cerebrolysin in heat stroke following intoxication of engineered metal Ag and Cu nanoparticles: A comparative biochemical and physiological study with other stroke therapies |
|
301 | (48) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
303 | (1) |
|
|
304 | (7) |
|
|
304 | (1) |
|
2.2 Exposure to heat stress |
|
|
304 | (1) |
|
2.3 Nanoparticles exposure |
|
|
305 | (1) |
|
|
305 | (1) |
|
2.5 Nanowired delivery of cerebrolysin (NWCBL) |
|
|
306 | (1) |
|
|
306 | (1) |
|
|
306 | (1) |
|
2.8 Physiological variables |
|
|
307 | (1) |
|
2.9 Blood-brain barrier breakdown |
|
|
307 | (1) |
|
|
308 | (1) |
|
2.11 Brain edema and volume swelling (%f) |
|
|
308 | (1) |
|
2.12 Oxidative stress parameters |
|
|
309 | (1) |
|
|
310 | (1) |
|
2.14 Statistical analyses of the data obtained |
|
|
311 | (1) |
|
|
311 | (22) |
|
3.1 Effect of heat stroke on stress symptoms |
|
|
311 | (1) |
|
3.2 Physiological variables |
|
|
311 | (4) |
|
3.3 Blood-brain barrier breakdown |
|
|
315 | (1) |
|
|
315 | (3) |
|
|
318 | (1) |
|
3.6 Oxidative stress parameters |
|
|
318 | (1) |
|
|
318 | (12) |
|
3.8 Effect of drug treatments on nanoparticles intoxication in heat stroke |
|
|
330 | (3) |
|
|
333 | (4) |
|
|
337 | (1) |
|
|
337 | (1) |
|
|
337 | (12) |
Chapter 9 A clinical study of high-dose urokinase for the treatment of the patients with hypertension induced ventricular hemorrhage |
|
349 | (8) |
|
|
|
|
|
|
|
|
350 | (2) |
|
|
350 | (1) |
|
|
351 | (1) |
|
|
351 | (1) |
|
|
351 | (1) |
|
1.5 Extubation indicators |
|
|
352 | (1) |
|
1.6 Assessment of therapeutic effect |
|
|
352 | (1) |
|
|
352 | (1) |
|
|
352 | (1) |
|
|
353 | (2) |
|
|
355 | (1) |
|
|
355 | (2) |
Chapter 10 Topical application of CNTF, GDNF and BDNF in combination attenuates blood-spinal cord barrier permeability, edema formation, hemeoxygenase-2 upregulation, and cord pathology |
|
357 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
358 | (1) |
|
|
359 | (2) |
|
|
359 | (1) |
|
|
359 | (1) |
|
2.3 Neurotrophins treatment |
|
|
360 | (1) |
|
2.4 Morphological investigations of the spinal cord |
|
|
360 | (1) |
|
2.5 Hemeoxygenase 2 immunostaining of the spinal cord |
|
|
360 | (1) |
|
2.6 Cell injury in the spinal cord |
|
|
360 | (1) |
|
2.7 Blood-spinal cord barrier permeability |
|
|
361 | (1) |
|
|
361 | (1) |
|
2.9 Spinal cord blood flow |
|
|
361 | (1) |
|
2.10 Statistical analyses of the data |
|
|
361 | (1) |
|
|
361 | (7) |
|
3.1 Effect of neurotrophins on HO-2 expression in the cord after trauma |
|
|
361 | (3) |
|
3.2 Effect of neurotrophins on neuronal injury in the cord after trauma |
|
|
364 | (1) |
|
3.3 Effect of neurotrophins on blood-spinal cord barrier permeability after trauma |
|
|
365 | (1) |
|
3.4 Effect of neurotrophins on spinal cord edema after trauma |
|
|
366 | (1) |
|
3.5 Effect of neurotrophins on spinal cord blood flow after trauma |
|
|
367 | (1) |
|
|
368 | (2) |
|
|
370 | (1) |
|
|
371 | (1) |
|
|
371 | (6) |
Chapter 11 Diagnosis experience and literature review of patients with cervical, thoracic and lumbar multi-segment spinal stenosis: A case report |
|
377 | |
|
|
|
|
|
|
|
378 | (1) |
|
|
378 | (3) |
|
|
381 | (2) |
|
|
383 | (1) |
|
|
383 | (1) |
|
|
383 | |